Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 2, 2016

View Archived Issues

New biomarkers in rheumatoid disease presented at ACR meeting

Arsanis' ASN-100 receives FDA fast track designation

ABC-1183, a novel GSK3/CDK9 inhibitor

EC grants orphan designation to Agilis Biotherapeutics' AGIL-AADC

AmorePacific initiates phase III trial of PAC-14028 in atopic dermatitis

Vertex initiates phase II study of VX-152 combination therapy for cystic fibrosis

A first-in-class small-molecule inhibitor of PD-L1 and TIM-3

Daiichi Sankyo's DS-8201 given FDA fast track designation

First phase Ia/b data for anti-RSPO3 antibody OMP-131R10 in advanced solid tumors

City of Hope and TGen form alliance to advance precision medicine

Axial Biotherapeutics launches with series A financing

Portage Biotech forms new ophthalmic-focused company

Kalyra Pharmaceuticals patents EGFR inhibitors

Wistar Institute discloses EBNA-1 inhibitors

GlaxoSmithKline describes RIP-1 kinase 1 inhibitors

Medshine Discovery develops PDE2A inhibitors and TNF-alpha production inhibitors

Kainos Medicine presents Brd4 inhibitors

Aequus BioPharma synthesizes melanocortin fusion peptide for treating gout

IONIS-ANGPTL3-LRx shows potential to reduce plasma ANGPTL3 and lipids

Ferring Pharmaceuticals and Ache Laboratorios Farmaceuticos form nanotechnology collaboration

Biophytis' Sarconeos safe in SARA-PK clinical study

Aradigm reports topline results from ORBIT-3 and -4 studies of Pulmaquin

Inovio Pharmaceuticals awarded grant for MAb against Zika virus

GALACTIC-HF phase III trial of omecamtiv mecarbil begins

HDAC6 inhibitor ACY-241 given U.S. orphan status for multiple myeloma

Dosing begins in phase I/II study of Agenus' INCAGN-1949

Shire's Cinryze granted U.S. orphan status for acute antibody-mediated renal transplant rejection

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...